Lexicon grants patented gene targeting technology license to GlaxoSmithkline.
"We are very pleased to have GlaxoSmithKline join the prestigious group of licensees to our patented gene targeting technologies," said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. "GlaxoSmithKline's license provides further affirmation that our patented gene targeting technologies are an integral resource to validate targets for drug discovery."
Lexicon is a drug discovery company of the post-genome era, using gene knockout technology to define the functions of genes for the discovery of pharmaceutical products. Lexicon is using this technology to fuel drug discovery programs in cancer, cardiovascular disease, immune disorders, neurological disease, diabetes and obesity. Lexicon has established drug discovery alli-ances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.
|Printer friendly Cite/link Email Feedback|
|Comment:||Lexicon grants patented gene targeting technology license to GlaxoSmithkline.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Aug 1, 2001|
|Previous Article:||Alfacell granted new European patent involving Onconase.|
|Next Article:||Phytomedics adds United States Patent to its nutraceutical portfolio.|